The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
Portfolio Pulse from Benzinga Insights
Collegium Pharmaceutical (NASDAQ:COLL) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target has increased to $44.0, up from $42.0. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Collegium's financials show strong net margins and ROE, but high debt levels pose challenges.
September 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Collegium Pharmaceutical has received predominantly bullish analyst ratings, with an increased average price target of $44.0. The company's financials are strong, but high debt levels could pose risks.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. The company's strong financial metrics like net margin and ROE support this view. However, the high debt-to-equity ratio is a concern, which could limit upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100